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ABSTRACT 
Objective: The objective of this study was to develop and validate a stability indicating reverse-phase HPLC method for simultaneous estimation of 
Ofloxacin and Flavoxate hydrochloride from their combination product.  
Methods: The proposed RP-HPLC method was developed using inertsil C18, 5 µm, 250 mm × 4.6 mm column. The mobile phase used was a mixture 
of methanol and water in the proportion of 50:50 (v/v) with apparent pH adjusted to 4.9, and UV detection at 274 nm using a PDA detector and 
Empower-2 software. The flow rate was 1.0 ml/min. Ofloxacin, Flavoxate hydrochloride and their combination drug product were exposed to 
thermal, photolytic, hydrolytic, and oxidative stress conditions, and the stressed samples were analysed by the proposed method.  
Results: With the optimized method, retention times of Ofloxacin and Flavoxate hydrochloride were found to be 4.3 and 2.98 respectively. Peak 
homogeneity data of Ofloxacin and Flavoxate hydrochloride peaks obtained using PDA detector, in the stressed sample chromatograms 
demonstrated the specificity of the method for their estimation in the presence of degradants. The described method was linear over a range of 10-
60 µg/ml with regression coefficient of 0.9996 and 0.9998. The mean recoveries were 99.57% and 99.99% for Ofloxacin and Flavoxate 
hydrochloride, respectively.  
Conclusion: Stress testing, which covered acid, alkali, peroxide, photolytic and thermal degradation was performed to prove the specificity of the 
proposed method and degradation, was achieved. The developed method was validated according to ICH guidelines and was found to be simple, 
precise and accurate with the prescribed values.  
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INTRODUCTION 
Chemically, Ofloxacin is (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-
methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-
6-carboxylic acid (fig. 1) and Flavoxate is 2-(1-piperidyl)ethyl-3-
methyl-4–oxo-2-phenyl-chromene-8-carboxylate (fig. 2). Ofloxacin is 
bactericidal and its mode of action depends on blocking of bacterial 
DNA replication by binding itself to an enzyme called DNA gyrase, 
which allows the untwisting required replicating one DNA double 
helix into two [1]. Notably the drug has 100 times higher affinity for 
bacterial DNA gyrase than for mammalian DNA.  
Flavoxate acts as a direct antagonist at muscarinic acetylcholine 
receptors in cholinergically innervated organ. Its anticholinergic 
parasympatholytic action reduces the tonus of smooth muscle in the 
bladder, effectively reducing the number of required voids, urge 
incontinence episodes, urge severity and improving retention, 
facilitating increased volume per void.  
Patients who had catheterization, urinary incontinence, and dysuria, 
in such case there is all chances of bacterial like Escherichia coli, 
Staphylococcus saprophyticus etc, in such case Ofloxacin is given in 
combination with Flavoxate [2]. 
 
  
Fig. 1: Structure of Ofloxacin (OFX) Fig. 2: Structure of Flavoxate (FLX) 
 
The concept of analytical chemistry lies in the precise and accurate 
measurements. This determination requires highly sophisticated 
instruments and methods like HPLC, Gas Chromatography, HPTLC, 
Spectrophotometry, Fluorimetry etc. Instrumental methods are 
sensitive, accurate, precise and desirable for regular determination 
of drug in formulations, thereby is advantageous than the 
conventional volumetric methods.  
On the literature survey, it was found that Ofloxacin was estimated 
independently and in combination with other drugs by several 
Chromatographic [3-10], Spectrometric [11] and Fluorimetric [12] 
methods in pharmaceutical formulations and in biological samples. 
Similarly Flavoxate was estimated by Ultraviolet Spectrophotometry 
[13], HPLC [14-17], Voltammetry [18], and Capillary electrophoresis 
[19] determination techniques. One analytical method was found for 
stability indicating simultaneous estimation of Ofloxacin and 
Flavoxate HCl in combination [20].  
In view of the need analytical method in the quality control 
laboratories for routine analysis of OFX (Ofloxacin) and FLX 
(Flavoxate hydrochloride) in formulations, attempts are being made 
to develop simple and accurate instrumental methods for 
simultaneous estimation of OFX and FLX, and extend it for their 
determination in formulation. The present work describes the 
development of a simple, precise, accurate and reproducible 
chromatographic method for the simultaneous estimation of OFX and 
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FLX in pharmaceutical dosage form. The developed method was 
validated in accordance with ICH Guidelines. 
MATERIALS AND METHODS 
Reagents 
Ofloxacin and Flavoxate HCl were purchased from Active Pharm 
Lab., Hyderabad. HPLC grade methanol and water were purchased 
from Merck (Mumbai). Sodium Hydroxide (AR Grade) and Hydrogen 
peroxide (AR Grade) were purchased from Merck (Mumbai). 
Instrumentation 
Water HPLC system (Water 2690/5) was used for method 
development and validation. The HPLC system was equipped with a 
binary pump, a temperature controlled auto-sampler and a photo-
diode array detector. The software used was Empower-2. 
Chromatographic condition 
The HPLC column used was Inertsil C-18 (250 × 4.6 mm, 5 µm 
particle size). Mobile phase comprised of a 50:50 (v/v) mixture of 
methanol and water. The pH of mobile phase was adjusted to 4.9 
with ortho-phosphoric acid. 1 ml/min flow rate was used for method 
development and validation. The auto-sampler temperature was set 
at 25 °C and the detection wavelength was 274 nm and an injection 
volume of 20 µl was used. 
Preparation of stock and standard solution 
Accurately weighed quantity of OFX and FLX (equivalent to 10 mg 
each) was transferred into two separate 100 ml volumetric flasks. 
The drugs were dissolved in 50 ml of mobile phase with shaking and 
sonicated for 10 min, and then the volume was made up to the mark 
with the mobile phase to obtain standard stock solution of each drug 
of concentration 100 µg/ml.  
Aliquots of standard stock solution of OFX and FLX were transferred 
using bulb pipettes into 10 ml volumetric flasks and, the solutions 
were made up to volume with mobile phase to yield final 
concentration of 10, 20, 30, 40, 50 and 60 µg/ml for both drugs. 
Calibration curves for OFX and FLX 
The marketed formulation contains OFX and FLX in a ratio of 1:1. 
Appropriate aliquots of OFX and FLX stock solutions were taken in 
different 10 ml volumetric flasks and diluted up to the mark with 
mobile phase to obtain final concentrations of 10-60 μg/ml of OFX and 
FLX. The solutions were injected using a 20 μl fixed loop system and 
chromatograms were recorded.  
Calibration curves were constructed by plotting average peak areas 
versus concentrations, and regression equations were computed for 
both the drugs (table 1). 
 
Table 1: Linear regression data for calibration curves of OFX and FLX 
Parameter OFX FLX 
Linearity range (µg/ml) 10-60 10-60 
Linear regression equation y = 37719x+24070 y = 78704x+137863 
r2 (Correlation coefficient) 0.9996 0.9998 
Slope  37719 78704 
Intercept 24070 137863 
SD 705811.8 1472597 
 
Preparation of tablets for assay 
Twenty Zenflox UTI tablets containing 200 mg each of OLX and FLX 
were weighed, crushed and mixed in a mortar and pestle for 20 min. 
A portion of powder equivalent to the 10 mg of OFX and FLX was 
accurately weighed and transferred to volumetric flask (100 ml) 
and, 50 ml of HPLC grade methanol was added to the flask. The 
volumetric flasks were sonicated for 10 min to effect complete 
dissolution of the OFX and FLX and the solutions were then made up 
to volume with HPLC grade water. Aliquots of the solutions were 
filtered through a 0.45 µm filter, and 1 ml of filtered solution was 
transferred to 10 ml volumetric flasks and made up to the volume 
with mobile phase, to yield concentration of each of the two drugs in 
the range of linearity previously described. 
Validation of the method 
The analytical method was validated with respect to parameters 
such as linearity, limit of quantitation (LOQ), limit of detection 
(LOD), precision, accuracy, recovery and robustness (table 2). 
 
Table 2: Summary of validation parameters for OFX and FLX 
Parameter OFX FLX 
Linearity range (µg/ml) 10-60 10-6110 
Correlation coefficient 0.9996 0.9998 
LOD (μg/ml) 0.363 0.196 
LOQ (μg/ml) 1.10 0.594 
Recovery (%) 99.57 99.99 
Precision (%RSD) 
Inter day (n=3) 
0.19 0.08 
Intraday (n=3) 0.09 0.05 
Robustness Robust Robust 
Retention Time 4.3 2.98 




The constructed calibration curves were linear over the 
concentration range of 10-60 µg/ml for both OFX and FLX. Peak 
areas of OFX and FLX were plotted versus their respective 
concentration and linear regression analysis performed on the 
resultant curves. Correlation coefficient R (with n=3) was found to 
be 0.9996 and 0.9998 for OFX and FLX respectively. Typically the 
regression equations were y = 37719x+24070 for OFX, and y = 
78704x+137863 for FLX respectively.  
LOD and LOQ 
The LOD and LOQ were separately determined based on the 
standard deviation of response of the calibration curve. The 
standard deviation of the ‘y’ intercept and ‘slope’ of the calibration 
curves was used. Following formula was used to calculate the LOD 
and LOQ values. 
The Limit of Detection = 3.3 × SD/S 
The Limit of Quantitation = 10 × SD/S 
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Where;  
SD = standard deviation 
S = slope of calibration curve 
Precision 
The intra-day and inter-day variability or precision data are 
summarized in table and was assessed by using the standard 
solution prepared to produce solution of 10 µg/ml concentration of 
each drug. Repeatability was investigated by injecting six replicate 
samples of each drug. Inter-day precision was assessed by injecting 
the same samples over three consecutive days.  
Accuracy 
Recovery studies were carried out at 80%, 100% and 120% level. 
The solutions were filtered through a 0.45 μm membrane filter 
paper and analyzed by RP-HPLC method. Recovery studies were 
carried out by applying the method to drug contents present in 
tablet dosage form to which known amount of standard OFX and 
standard FLX was added at 80%, 100% and 120% levels. The 
technique includes an addition of standard drug solution to pre-
analysed sample solution. The recovery study was performed three 
times at each level.  
Specificity 
The specificity of the HPLC method was ascertained by analyzing 
standard drug and sample solutions. The retention times of OFX and FLX 
in the sample solution were confirmed not only by comparing with that 
of the respective standards but also using the diodarray. The 
chromatogram of tablet sample showed only two peaks at retention time 
of 4.3 and 2.98 mins for OFX and FLX respectively, indicating that there is 
no interference of the excipients in the tablet formulation.  
Robustness test 
The robustness of the study was carried out to evaluate the influence 
of small but deliberate variations in the chromatographic conditions. 
We have measured the effect of deliberate changes on peak area as 
well as on retention time. The factors chosen for this study were the 
flow rate, mobile phase composition and temperature.  
Forced degradation study 
In order to establish whether the analytical method was stability 
indicating, marketed formulation of OFX and FLX was stressed 
under various conditions to conduct forced degradation studies. As 
these drugs are freely soluble and stable in methanol, methanol was 
used as a solvent in all forced degradation studies.  
Oxidative studies 
In oxidative studies, marketed formulation was treated with 6% 
H2O2, kept for three hours then volume were made with methanol 
and the solution was analysed.  
Acid degradation studies 
Solutions for acid degradation studies, was prepared in methanol 
and 0.1 N hydrochloric acid. The resultant solutions were analysed 
after 3 hours. 
Alkaline degradation studies 
Solutions for alkaline degradation studies, was prepared in 
methanol and 1 N sodium hydroxide. The resultant solutions were 
analysed after 3 hours. 
Thermal degradation studies 
Marketed formulation was powdered and then exposed to dry heat 
of 50 °C in a convection oven for 6 hours. The powder was removed 
from the oven and powder equivalent to the 10 mg for both drugs, was 
weighed and then solutions were prepared in methanol and analysed. 
Photostability studies 
Marketed formulation was powdered, and the powder was exposed 
to the short wavelength (254 nm) of UV light for 10 hours. After that, 
powder equivalent to the 10 mg for both drugs was weighed and 
then solutions were prepared in methanol and analysed. 
RESULTS AND DISCUSSION 
An Inertsil C-18, 250 mm × 4.6 mm i.d. Column maintained at 
ambient temperature (25 °C) was used for the separation and 
method validation for the determination of OFX and FLX in Zenflox 
UTI tablets. The composition, pH and the flow rate of the mobile 
phase were changed to optimize the separation condition using 
stressed samples and the main related substances of the two 
compounds of interest.  
The HPLC method was optimized to develop a stability indicating 
assay method for the quantitative determination of OFX and FLX 
from tablet dosage form. Initially methanol-water in varying ratios 
was tried as the mobile phase. The mobile phase consisting of 
methanol and water (50:50 v/v), pH adjusted to 4.9 with ortho-
phosphoric acid gave good results. The flow rate of 1 ml/min was 
selected for use for further studies after several preliminary 
investigatory chromatographic runs. Under the described 
experimental condition, all the peaks were well defined and free 
from tailing. The effect of small deliberate changes in the mobile 
phase composition, pH and flow rate, was evaluated as a part of 
testing for method robustness.  
The retention times of OFX and FLX were found to be 4.3 and 2.98 
respectively (fig. 3).  
 
 
Fig. 3: Chromatogram of market formulation of OFX and FLX 
 
All stressed samples tested in the solid state and in solution 
remained color less following testing and, OFX and FLX were found 
to be relatively stable following exposure to dry heat and the UV 
light. No degradation peaks were observed under photolytic and 
thermal degradation condition for OFX and FLX (fig. 4 and fig. 5).  
 
 




Fig. 5: Chromatogram of mixture of OFX and FLX under thermal 
condition 
 
FLX was found to be more stable under alkaline condition rather 
than under acidic stress condition. FLX decomposed to 16.22%, 
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8.03%, 4.9% under acidic, alkaline and oxidative stress condition 
respectively. On the other hand, OFX decomposed to 10.23% and 
3.1%, under alkaline and oxidative stress conditions respectively 
and no degradation was observed under acidic stress condition.  
One additional peak was observed at 2.10 in the chromatogram of 
the mixture of OFX and FLX under acidic conditions.  
Under alkaline conditions, two additional peaks were observed for 
the combination, one at 2.03 and other one at 3.24, whereas under 
oxidative conditions, three peaks were observed. (fig. 6 to fig. 8). 
 
 
Fig. 6: Chromatogram of mixture of OFX and FLX degraded 
under acidic condition 
 
 
Fig. 7: Chromatogram of mixture of OFX and FLX degraded 
under alkaline conditions 
 
 
Fig. 8: Chromatogram of mixture of OFX and FLX degraded 
under oxidative condition 
The forced degradation studies were summarized (table 3).  
Table 3: Summary of degradation studies for OFX and FLX 
S. No. Parameter % Degradation (±SD, n = 3) 
OFX FLX 
1 Acidic Degradation ND 16.22%±5.49  
2 Alkali Degradation 10.23%±1.06 8.03%±3.74  
3 Oxidative Degradation 3.1%±4.27  4.9%±2.11  
4 Thermal Degradation ND ND 
5 Photo Degradation ND ND 
ND–No degradation observed 
 
CONCLUSION 
A simple, rapid, accurate and precise stability indicating HPLC 
analytical method has been developed and validated for the routine 
analysis of OFX and FLX. The results of stress testing undertaken 
according to the International Conference on Harmonization 
guidelines reveal that the method is selective and stability–
indicating. The proposed method has the ability to separate these 
drugs from their degradation products, related substances or 
excipients found in tablet dosage forms. 
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